These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 15262898

  • 1. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 2. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS, Graham LJ, Hamad GG, George KR, Bear HD.
    J Surg Res; 2001 Jun 15; 98(2):108-15. PubMed ID: 11397126
    [Abstract] [Full Text] [Related]

  • 3. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD.
    Cancer Res; 1992 Feb 01; 52(3):548-53. PubMed ID: 1732041
    [Abstract] [Full Text] [Related]

  • 4. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE, Touhalisky JE, Shu S.
    Cell Immunol; 1997 Jun 15; 178(2):101-7. PubMed ID: 9225000
    [Abstract] [Full Text] [Related]

  • 5. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD.
    Cancer Res; 1993 Feb 15; 53(4):833-9. PubMed ID: 8428364
    [Abstract] [Full Text] [Related]

  • 6. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z, Fan H, Wu Y, Chen B.
    Cytotherapy; 2005 Feb 15; 7(4):353-62. PubMed ID: 16162457
    [Abstract] [Full Text] [Related]

  • 7. Precursor frequency analysis of bryostatin activated lymphocytes.
    Fleming MD, Barrett SK, Bear HD.
    J Surg Res; 1994 Jul 15; 57(1):74-9. PubMed ID: 8041153
    [Abstract] [Full Text] [Related]

  • 8. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Parviz M, Chin CS, Graham LJ, Miller C, Lee C, George K, Bear HD.
    Cancer Immunol Immunother; 2003 Dec 15; 52(12):739-50. PubMed ID: 12827306
    [Abstract] [Full Text] [Related]

  • 9. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 10. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H, Chang AE, Shu SY.
    Cancer Res; 1992 Mar 01; 52(5):1129-36. PubMed ID: 1531321
    [Abstract] [Full Text] [Related]

  • 11. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 01; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

  • 12. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H, Shu S.
    J Immunol; 1998 Apr 01; 160(7):3444-52. PubMed ID: 9531305
    [Abstract] [Full Text] [Related]

  • 13. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
    Miller CH, Graham L, Bear HD.
    BMC Immunol; 2010 Nov 04; 11():54. PubMed ID: 21050466
    [Abstract] [Full Text] [Related]

  • 14. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
    Meijer SL, Dols A, Hu HM, Chu Y, Romero P, Urba WJ, Fox BA.
    Cell Immunol; 2004 Feb 04; 227(2):93-102. PubMed ID: 15135291
    [Abstract] [Full Text] [Related]

  • 15. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial.
    Cerwenka A, Morgan TM, Dutton RW.
    J Immunol; 1999 Nov 15; 163(10):5535-43. PubMed ID: 10553081
    [Abstract] [Full Text] [Related]

  • 16. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 17. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD.
    Cancer Immunol Immunother; 2009 Oct 15; 58(10):1565-76. PubMed ID: 19198835
    [Abstract] [Full Text] [Related]

  • 18. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.
    Cancer Res; 2001 Feb 01; 61(3):880-3. PubMed ID: 11221874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.